These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24708696)

  • 1. Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up.
    van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Kleefstra N; Bilo HJ
    BMC Endocr Disord; 2014 Apr; 14():30. PubMed ID: 24708696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report of a 7 year case-control study of continuous intraperitoneal insulin infusion and subcutaneous insulin therapy among patients with poorly controlled type 1 diabetes mellitus: favourable effects on hypoglycaemic episodes.
    van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Bilo HJ; Kleefstra N
    Diabetes Res Clin Pract; 2014 Nov; 106(2):256-63. PubMed ID: 25305134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal versus subcutaneous insulin therapy in the treatment of type 1 diabetes mellitus.
    van Dijk PR; Logtenberg SJ; Hendriks SH; Groenier KH; Feenstra J; Pouwer F; Gans RO; Kleefstra N; Bilo HJ
    Neth J Med; 2015 Nov; 73(9):399-409. PubMed ID: 26582805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability.
    van Dijk PR; Groenier KH; DeVries JH; Gans RO; Kleefstra N; Bilo HJ; Logtenberg SJ
    Diabetes Technol Ther; 2015 Jun; 17(6):379-84. PubMed ID: 25856045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic control, health status and treatment satisfaction with continuous intraperitoneal insulin infusion.
    Logtenberg SJ; van Ballegooie E; Israêl-Bultman H; van Linde A; Bilo HJ
    Neth J Med; 2007 Feb; 65(2):65-70. PubMed ID: 17379931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. After 6years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    Growth Horm IGF Res; 2015 Dec; 25(6):316-9. PubMed ID: 26336814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial.
    Logtenberg SJ; Kleefstra N; Houweling ST; Groenier KH; Gans RO; van Ballegooie E; Bilo HJ
    Diabetes Care; 2009 Aug; 32(8):1372-7. PubMed ID: 19429874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Optimized Percutaneous Access System for CIPII.
    Garcia-Verdugo R; Erbach M; Schnell O
    J Diabetes Sci Technol; 2017 Jul; 11(4):814-821. PubMed ID: 28654300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.
    Oskarsson PR; Lins PE; Backman L; Adamson UC
    Diabetes Metab; 2000 Apr; 26(2):118-24. PubMed ID: 10804326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A systematic review and meta-analysis.
    Dirnena-Fusini I; Åm MK; Fougner AL; Carlsen SM; Christiansen SC
    PLoS One; 2021; 16(4):e0249611. PubMed ID: 33848314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study.
    Dassau E; Renard E; Place J; Farret A; Pelletier MJ; Lee J; Huyett LM; Chakrabarty A; Doyle FJ; Zisser HC
    Diabetes Obes Metab; 2017 Dec; 19(12):1698-1705. PubMed ID: 28474383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life, treatment satisfaction, and costs associated with intraperitoneal versus subcutaneous insulin administration in type 1 diabetes: a randomized controlled trial.
    Logtenberg SJ; Kleefstra N; Houweling ST; Groenier KH; Gans RO; Bilo HJ
    Diabetes Care; 2010 Jun; 33(6):1169-72. PubMed ID: 20185731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
    Lind M; Polonsky W; Hirsch IB; Heise T; Bolinder J; Dahlqvist S; Schwarz E; Ólafsdóttir AF; Frid A; Wedel H; Ahlén E; Nyström T; Hellman J
    JAMA; 2017 Jan; 317(4):379-387. PubMed ID: 28118454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of programmable implantable insulin delivery systems.
    Olsen CL; Liu G; Iravani M; Nguyen S; Khourdadjian K; Turner DS; Waxman K; Selam JL; Charles MA
    Int J Artif Organs; 1993 Dec; 16(12):847-54. PubMed ID: 8175202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.
    Liebl A; Hoogma R; Renard E; Geelhoed-Duijvestijn PH; Klein E; Diglas J; Kessler L; Melki V; Diem P; Brun JM; Schaepelynck-Bélicar P; Frei T;
    Diabetes Obes Metab; 2009 Nov; 11(11):1001-8. PubMed ID: 19740082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2493-501. PubMed ID: 27115061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous insulin infusion (CSII) therapy at Derby Teaching Hospitals: sustained benefits in glucose control.
    Anyanwagu U; Olaoye H; Jennings P; Ashton-Cleary S; Sugunendran S; Hughes D; Idris I; Wilmot EG
    Diabet Med; 2017 Aug; 34(8):1154-1157. PubMed ID: 28430381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study.
    Charleer S; De Block C; Nobels F; Radermecker RP; Lowyck I; Mullens A; Scarnière D; Spincemaille K; Strivay M; Weber E; Taes Y; Vercammen C; Keymeulen B; Mathieu C; Gillard P;
    Diabetes Care; 2020 Dec; 43(12):3016-3023. PubMed ID: 33067260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.